Key clinical point: Survivors of childhood non-Hodgkin lymphoma (NHL) may carry BRCA2 mutations.
Major finding: NHL survivors who were BRCA2 mutation carriers had a fivefold higher cancer risk than control carriers.
Study details: Retrospective genomic study of 1,380 survivors of childhood lymphomas and controls without cancer from the Genome Aggregation Database.
Disclosures: This study was funded by a grant to St Jude Children’s Research Hospital from the American Lebanese Syrian Associated Charities and by grants to St Jude Children’s Research Hospital from the National Institutes of Health. The authors reported having no conflicts of interest.
Wang Z et al. JAMA Oncology. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2203.